Medication price news
Two things sit here. What prices are actually doing, written from the checks we run across UK pharmacies every day — and the outside reporting that moved this market, linked to whoever published it.
From our price data
Mounjaro 2.5mg costs £130.99 more at the dearest UK pharmacy than the cheapest
Mounjaro 2.5mg ranges from £119.00 to £249.99 across 25 UK pharmacies checked in the last 7 days — the same medicine, 110% more expensive at one end than the other.
Mounjaro 2.5mg costs £130.99 more at the dearest UK pharmacy than the cheapest
Mounjaro 2.5mg ranges from £119.00 to £249.99 across 26 UK pharmacies checked in the last 7 days — the same medicine, 110% more expensive at one end than the other.
Mounjaro 2.5mg costs £130.99 more at the dearest UK pharmacy than the cheapest
Mounjaro 2.5mg ranges from £119.00 to £249.99 across 26 UK pharmacies checked in the last 7 days — the same medicine, 110% more expensive at one end than the other.
Mounjaro 2.5mg costs £130.99 more at the dearest UK pharmacy than the cheapest
Mounjaro 2.5mg ranges from £119.00 to £249.99 across 25 UK pharmacies checked in the last 7 days — the same medicine, 110% more expensive at one end than the other.
Mounjaro 2.5mg costs £130.99 more at the dearest UK pharmacy than the cheapest
Mounjaro 2.5mg ranges from £119.00 to £249.99 across 26 UK pharmacies checked in the last 7 days — the same medicine, 110% more expensive at one end than the other.
Mounjaro 2.5mg costs £130.99 more at the dearest UK pharmacy than the cheapest
Mounjaro 2.5mg ranges from £119.00 to £249.99 across 27 UK pharmacies checked in the last 7 days — the same medicine, 110% more expensive at one end than the other.
Mounjaro 2.5mg costs £130.99 more at the dearest UK pharmacy than the cheapest
Mounjaro 2.5mg ranges from £119.00 to £249.99 across 29 UK pharmacies checked in the last 7 days — the same medicine, 110% more expensive at one end than the other.
Mounjaro 2.5mg costs £130.99 more at the dearest UK pharmacy than the cheapest
Mounjaro 2.5mg ranges from £119.00 to £249.99 across 28 UK pharmacies checked in the last 7 days — the same medicine, 110% more expensive at one end than the other.
Mounjaro 2.5mg costs £110.00 more at the dearest UK pharmacy than the cheapest
Mounjaro 2.5mg ranges from £139.99 to £249.99 across 27 UK pharmacies checked in the last 7 days — the same medicine, 79% more expensive at one end than the other.
Market news
Weight Loss
UK trial to test whether semaglutide reduces alcohol cravings
A study led in part by the University of Plymouth will examine whether semaglutide can reduce alcohol cravings as well as producing weight loss. An early-stage question rather than a licensed use — but it is the kind of finding that widens who gets prescribed these medicines, and therefore what they cost.
Survey suggests aesthetic goals, not health, are driving demand for weight-loss medicines
Reported by The Pharmaceutical Journal: 78% of 1,574 respondents indicated short-term aesthetic goals rather than health reasons as the driver for using or considering weight-loss medication. Worth noting who paid for it — the survey was commissioned by LloydsPharmacy Online Doctor, a provider of the kind this site compares on price.
Orforglipron weight-loss pill authorised for use in the UK
The MHRA authorised Eli Lilly's daily oral GLP-1 orforglipron, making the UK the first country in Europe to approve it. A second oral entrant matters for anyone comparing prices: injectables have had the private market largely to themselves, and this one is a small molecule rather than a peptide, which changes the manufacturing picture.
UK sites recruiting for phase III trials of a new dual-agonist weight-loss drug
Trial sites in England including Manchester, Truro and Hull are recruiting for the KAINETIC phase III studies of ribupatide, an investigational dual GLP-1 and GIP receptor agonist — the same mechanism class as tirzepatide. Years from any UK licence, but it is the pipeline that eventually decides whether this market gets more competitive.
How NHS access to weight-management injections actually works
NHS England's standing guidance on obesity medicines: semaglutide is prescribed only through specialist weight management services, while tirzepatide is moving into primary care in phases. Useful context if you are weighing NHS access against paying privately.
A clinical guide to switching between weight-loss medicines
A practitioner-facing review of moving between semaglutide and tirzepatide — why the doses do not map across, and what has to be considered when transferring someone mid-treatment. Relevant to anyone changing provider or medicine on price: the switch is a clinical decision, not an administrative one.
Regulator launches public campaign on fake online pharmacies after the weight-loss pill launch
With oral semaglutide reaching the market, the GPhC ran a campaign from 9 July 2026 urging the public to check that an online pharmacy is on its register, with materials on how to spot a fake site. A new format tends to bring a wave of new sellers, and the register is the check that separates them from the real ones.
Three-quarters of pharmacies expect a surge in demand for the weight-loss pill
A National Pharmacy Association survey of 310 UK pharmacy owners, published on 6 July 2026, found 76% expect to start significant numbers of eligible patients on oral semaglutide. Expect prices in a newly launched format to move as that demand lands — the early figure a provider quotes is unlikely to be where it settles.
Semaglutide approved to treat a form of liver disease
Wegovy gained a conditional authorisation for MASH — liver inflammation and scarring linked to excess liver fat — in adults with moderate-to-advanced fibrosis. A different indication from weight management, not yet on the NHS pending a NICE appraisal, and following the same dose ladder up to 2.4mg.
More than half of people who stop weight-loss medication restart within a year
Research presented at the Endocrine Society's ENDO 2026 conference, drawn from insurance claims data, found that more than half of patients who stopped GLP-1 treatment restarted within one year and nearly two thirds within two. It is the clearest argument yet for pricing these medicines as an ongoing annual cost rather than a course with an end date.
First GLP-1 tablet for weight loss approved in the UK
The MHRA approved an oral form of semaglutide for adults with a BMI of 30 or above, or 27 and above with a weight-related condition. Doses run 1.5mg, 4mg, 9mg and 25mg daily, at least a month apart. It is not available on the NHS, and a tablet is a different cost structure from a cold-chain pen — worth watching as private pricing settles.
MHRA's largest ever seizure of unlicensed weight-loss medicines, with two arrests
Investigators raided a country estate near Northampton and recovered around 12,000 doses of unlicensed weight-loss medicines, believed to have been manufactured and distributed from the site. The haul included retatrutide and tirzepatide alongside other peptide products. Retatrutide is not a licensed medicine in the UK, which is worth knowing if you see it offered anywhere at any price.
Regulator tells pharmacies to strengthen safeguards in weight management services
Following a review of its own inspections and the concerns raised with it, the GPhC called on pharmacies providing weight management services to strengthen their safeguards and governance. The findings behind it describe supply to people who did not meet eligibility criteria, absent clinical assessment, and medicines supplied with no prescriber interaction at all — the failure modes to check a provider against before choosing one on price.
Single-dose 7.2mg Wegovy pen approved, replacing three separate injections
The MHRA approved a single-dose 7.2mg semaglutide pen for adults with a BMI of 30 or above. The dose was previously delivered as three 2.4mg injections a week, so this is a change in what a patient actually does — and a separate product for pharmacies to price.
NHS England updates its phased plan for rolling tirzepatide into primary care
The interim commissioning guidance behind TA1026 was reviewed in April 2026, with primary care costs folded into QOF 2026/27. It sets out who gets access first and over what timescale — the reason NHS supply reaches so few of those eligible.
Orforglipron beat oral semaglutide on weight and blood sugar in a phase III trial
The ACHIEVE-3 trial reported that the oral GLP-1 orforglipron produced better blood glucose control and more weight loss than oral semaglutide in people with type 2 diabetes — the only head-to-head between the two weight-loss pills now licensed in the UK. Trial conditions are not the private market, but this is the comparison that will shape how both are priced.
GPs offered up to £3,000 a year to prescribe Mounjaro as NHS rollout widens
From the April 2026 GP contract, practices in England can earn up to £3,000 a year for tirzepatide prescriptions and £1,000 for weight-management referrals, backed by £25m. Eligibility widens from BMI 40 to BMI 35, targeting 220,000 NHS patients by 2028.
Falsified Mounjaro KwikPen 15mg pens reached patients through a UK pharmacy
Eli Lilly reported five fake 15mg KwikPens, all batch D873576, supplied by a single Birmingham pharmacy. They do contain tirzepatide, but the MHRA cannot confirm the contents are sterile because the manufacturing conditions are unknown. They were spotted because the dose knob came off in use. Check the batch number and strength on your pen.
MHRA seizures of illegal weight-loss injections climb sharply
The regulator's February 2026 safety roundup covers enforcement against counterfeit GLP-1 supply, including the dismantling of illicit manufacturing in the UK. Buying a weight-loss pen outside a GPhC-registered pharmacy carries a real risk of a falsified product.
Semaglutide product information updated over a very rare eye condition
The MHRA updated product information regarding the very rare risk of non-arteritic anterior ischaemic optic neuropathy (NAION) — a sudden loss of vision caused by reduced blood flow to the optic nerve — in patients taking semaglutide. Sudden vision changes on a GLP-1 warrant urgent medical attention rather than an optician appointment next week.
MHRA strengthens pancreatitis warnings for GLP-1 medicines
Product information was updated over the risk of severe acute pancreatitis, including necrotising and fatal cases. The MHRA logged 1,296 Yellow Card reports of pancreatitis with GLP-1 medicines between 2007 and October 2025, against an estimated 1.6 million UK adults using one for weight loss in a single year. Severe, persistent stomach pain spreading to the back needs urgent assessment.
Nearly half of weight-loss medication users change their dosing to save money
A survey by LloydsPharmacy Online Doctor found 47% of people taking weight-loss medication had modified their dosing regimen to reduce what they spend, with 24% taking smaller doses than prescribed. Stretching a pen is a rational response to a price, and a clinically poor one — which is an argument for finding a cheaper provider rather than a smaller dose.
Regulator approves the 7.2mg dose of Wegovy for patients with obesity only
The MHRA authorised semaglutide at up to 7.2mg a week for adults with a BMI of 30 or above — a tighter licence than the doses below it, which reach patients from a BMI of 27 with a weight-related condition. It is not a starting dose: patients escalate to 2.4mg over about 20 weeks first. A new strength at the top of the ladder is a new pricing decision at every pharmacy.
Pharmacists warn the higher Wegovy dose could raise patient expectations
After the MHRA licensed the 7.2mg dose of Wegovy on 6 January 2026, the Pharmacists' Defence Association said prescribers should not feel pushed towards any specific medicine or dose, and that decisions must rest on clinical judgement. The Royal Pharmaceutical Society added that the higher strength should only be supplied where it is clinically appropriate. A dose being available is not a reason to be moved onto it.
Pharmacies now fail inspection if they do not independently verify weight and BMI
The GPhC's updated inspection framework, published on 13 January 2026, makes independent verification of a patient's weight, height and/or BMI a condition of passing inspection when supplying weight-loss medication. It replaces the 2019 framework and adds guidance on supervision, hub-and-spoke and prescribing. A questionnaire that simply accepts your typed numbers is now an inspection failure, not merely poor practice.
Regulator acts after online pharmacies accepted AI-generated images as weight verification
Trade reporting on GPhC action against online pharmacies that failed to carry out full and appropriate checks when prescribing weight-loss injections, after an ITV News investigation found people with healthy BMIs using AI-generated images to fake their weight. The rule requiring independent verification only works if what is submitted is real.
Regulators restate that prescription weight-loss medicines cannot be advertised to the public
The MHRA, the Advertising Standards Authority and the General Pharmaceutical Council issued a joint reminder that advertising prescription-only weight-loss medicines to the public is illegal. It is the reason a UK pharmacy's marketing talks around the medicine rather than naming it — and the reason a comparison has to be built from prices rather than from advertising.
Price increases reshaped what UK pharmacies charge for weight-loss treatment
Trade coverage of how the increase landed across the pharmacy sector, and why the gap between the cheapest and dearest provider widened rather than closed after it.
UK's largest online pharmacy froze its Mounjaro price as others raised theirs
Pharmacy2U said it would hold its Mounjaro prices for weight-loss patients until further notice despite the manufacturer's list price increase — one of the clearest signs that private prices would diverge sharply between providers.
NHS Mounjaro prescriptions reimbursed at the raised prices from September
An agreement between the Department of Health and Social Care and Community Pharmacy England set NHS reimbursement for Mounjaro at the increased UK prices. The NHS and private routes are priced by entirely separate mechanisms, which is why an NHS prescription charge tells you nothing about what the same medicine costs privately.
Patients struggled to obtain Mounjaro ahead of the price rise
Demand surged before the September 2025 increase. Lilly asked UK distributors to stop taking pharmacy orders over concerns about stockpiling, and pharmacies began prioritising existing patients over new starts.
Rebate scheme introduced for pharmacies after the Mounjaro price rise
Following the manufacturer's UK list price increase, a rebate scheme was introduced for pharmacies offering private weight management services, with the same terms said to be offered to all. It is part of why private Mounjaro prices did not simply move in step with the list price — and why the gap between providers widened instead of closing.
MHRA issues patient guidance on switching between weight-loss injections
The regulator published patient-facing advice on moving between GLP-1 weight-loss medicines. Switching for price is common and legitimate; doing it without a prescriber setting the starting dose is where people run into trouble, because the strengths of these medicines are not interchangeable numbers.
Mounjaro list price rose by up to 170% for private UK patients
From 1 September 2025 Eli Lilly raised the UK list price of Mounjaro — about 45% at the 2.5mg starter dose and roughly 170% at 15mg, which moved from £122 to £330. The NHS price was not affected.
MHRA publishes plain-English guidance for people taking GLP-1 medicines
A patient-facing summary covering what GLP-1 medicines are, the side effects to watch for, buying safely, pregnancy and contraception, and telling other healthcare professionals you are taking one. Worth reading before an online questionnaire rather than after — it is the checklist a good consultation should cover.
Women taking GLP-1 medicines told to use effective contraception
MHRA guidance says GLP-1 receptor agonists should not be used in pregnancy, and that women taking tirzepatide need a non-oral contraceptive — the medicine can reduce how well the oral pill is absorbed, most notably when starting or increasing the dose. A detail easily lost in an online questionnaire.
A photograph alone is not acceptable verification for weight-loss prescribing
The GPhC clarified that it is not appropriate to rely solely on a photograph or pre-recorded video to verify a patient's information when supplying weight-management medicines. Worth knowing what your provider is doing: an upload is not the same as verification, and the regulator has said so directly.
GLP-1 medicines carry a risk of pulmonary aspiration under general anaesthesia
An MHRA drug safety update set out that GLP-1 and dual GIP/GLP-1 receptor agonists slow gastric emptying, raising the risk that stomach contents enter the lungs during general anaesthesia or deep sedation. Current UK advice is not to stop the medicine on your own but to tell the anaesthetist and pre-operative team — including if it was prescribed privately.
NICE recommends tirzepatide on the NHS for BMI 35 and above with a weight-related condition
Technology appraisal TA1026 sets the clinical bar for NHS tirzepatide: BMI of at least 35, or 32.5 with ethnic adjustment, plus at least one weight-related comorbidity. Private prescribing is not bound by these thresholds.
MHRA reminder on GLP-1 side effects and the potential for misuse
A drug safety update reminding prescribers and patients of the recognised side effects of GLP-1 receptor agonists and warning about misuse — including supply obtained outside the legitimate chain and use by people who do not meet the criteria. Relevant to anyone shopping purely on price: the cheapest supply is sometimes the one that asked the fewest questions.
Semaglutide became the first weight-loss medicine licensed to prevent cardiovascular events
The MHRA approved Wegovy to reduce the risk of cardiovascular death, non-fatal heart attack and non-fatal stroke in adults with established cardiovascular disease and a BMI of 27 or above. In a trial of over 17,600 people, major adverse cardiovascular events fell by 20%. It is a separate indication from weight management, and it is why some patients are prescribed it who are not seeking weight loss.
Falsified Ozempic pens were found at UK wholesalers, not just on the black market
The MHRA reported falsified semaglutide pens identified at two UK wholesalers. The significance is where they turned up: this was the regulated supply chain, not a social media seller. It is why batch numbers and packaging checks matter even when a medicine comes from a registered pharmacy.
Hair Loss
Regulator: supplying finasteride at a distance carries particular risk
The GPhC's position on finasteride provision, last updated in August 2026, sets out why online supply of finasteride 1mg for hair loss needs particular care — it is a private prescription medicine, overwhelmingly bought online, for a cosmetic indication, carrying psychiatric and sexual side-effect warnings the MHRA has twice strengthened. A useful standard to hold a hair-loss service against.
MHRA issues public warning on finasteride after review of psychiatric side effects
The regulator's public announcement accompanying its safety review. Patients are told to stop and seek medical advice if they develop depression or suicidal thoughts, and prescribers to ask about psychiatric history before starting treatment.
MHRA strengthens finasteride and dutasteride warnings over psychiatric and sexual side effects
The MHRA has updated product information for finasteride 1mg and dutasteride, advising prescribers to ask about a history of depression or suicidal ideation first and to monitor afterwards. Patients who develop depression or suicidal thoughts should stop and seek advice.
New JAK inhibitor approved for severe alopecia areata
The MHRA approved deuruxolitinib (Leqselvi) for severe alopecia areata in adults — an autoimmune condition, quite distinct from male pattern hair loss. Across two trials in 1,223 patients, about 30% reached 80% or more scalp hair coverage at 24 weeks. It is a prescription-only twice-daily tablet, and NHS funding follows a separate NICE process.
Pharmacies told to carry out a robust assessment before supplying finasteride
The pharmacy regulator advised that teams carry out a robust assessment before supplying finasteride, given its recognised psychiatric and sexual side effects. Finasteride is bought almost entirely privately and online in the UK, so the quality of that assessment varies far more between providers than the price of the tablets does.
Patient alert card introduced for men taking finasteride
Following a safety review, the MHRA introduced an alert card in finasteride packs covering psychiatric and sexual side effects, which it noted may persist after stopping. By 5 April 2024 it had received 281 reports of depressed mood disorders and suicidal or self-injurious behaviour, and 426 of sexual dysfunction. The card is meant to be shared with family, since mood changes are often easier for others to notice.
NICE recommends the first NHS treatment for severe alopecia areata
NICE recommended ritlecitinib for severe alopecia areata in people aged 12 and over, estimating up to 14,000 people in England could benefit — the first time a medicine for the condition has been recommended for NHS use, and just 16 weeks after its licence. For a condition usually left to private clinics, an NHS route is the more important fact than the price.
Ritlecitinib authorised for severe alopecia areata in people aged 12 and over
The MHRA authorised Litfulo (ritlecitinib), which reduces the activity of JAK3 and TEC kinases involved in inflammation at the hair follicle. Alopecia areata is an autoimmune condition and is a different problem from male pattern hair loss — finasteride and minoxidil are not treatments for it.
NICE technology appraisal on baricitinib for severe alopecia areata
The NHS appraisal for the other JAK inhibitor used in severe alopecia areata. Alopecia areata is autoimmune and is a different condition from male or female pattern hair loss — which matters commercially as well as clinically, because it has an NHS route through dermatology, whereas pattern hair loss is treated as cosmetic and paid for privately.
ED Treatment
Online pharmacies must verify more than a questionnaire for higher-risk medicines
GPhC guidance requires prescribers not to rely on an online questionnaire alone for higher-risk medicines, but to verify independently — two-way contact, clinical records, or the patient's GP. A useful test of whether a provider is doing it properly.
Millions of illegal erectile dysfunction pills seized as MHRA warns against unauthorised sellers
Enforcement figures show roughly 20 million illegal ED tablets seized in the UK over five years. The regulator's advice is to buy only from a GPhC-registered pharmacy, whose registration can be checked on the public register.
Three decades of Viagra, charted
The Pharmaceutical Journal traces sildenafil from a failed angina candidate to the first oral ED treatment and on to generic and pharmacy-supply status — the shift that made today's price range possible.
Two million doses of illegal medicines intercepted at the UK border in a fortnight
Operation Pangea XVIII ran from 10 to 23 March 2026, with the MHRA and Border Force seizing more than 2 million doses valued at £4.6m. The products most commonly intercepted were associated with sedation, pain relief and erectile dysfunction. ED medicines remain among the most heavily counterfeited categories reaching UK buyers.
Concern over the rise of private testosterone replacement prescribing
A feature examining the growth of private testosterone replacement therapy in the UK, including criticism that some clinics apply liberal reference ranges and prescribe higher doses than the NHS would. Relevant to erectile dysfunction because low testosterone genuinely can blunt the response to PDE5 inhibitors — and because "low T" is also an effective way to sell a subscription.
MHRA and eBay work together to block illegal medicine listings
The MHRA described its partnership with eBay to identify and remove listings for prescription-only and non-compliant medicines, using an algorithm that has blocked millions of policy violations before sale. Erectile dysfunction medicines are among the most heavily counterfeited categories in the UK, and marketplaces are where much of it surfaces.
How the four PDE5 inhibitors actually differ
A pharmacy-focused review of sildenafil, tadalafil, vardenafil and avanafil — onset, duration, food effects and what the differences mean now that some are available without a prescription. Useful background if you are comparing prices across molecules rather than across pharmacies.
Tadalafil 10mg reclassified so it can be sold without a prescription
Cialis Together (tadalafil 10mg) became a Pharmacy medicine, sold to men over 18 after a discussion with the pharmacist, one tablet a day, maximum pack of eight. Men with severe cardiovascular disease, high cardiovascular risk or severe kidney or liver failure still need a prescription. It is why a tadalafil price can look so different over the counter than through a prescription service.
Sildenafil 50mg reclassified as a Pharmacy medicine
The reclassification of Viagra Connect moved sildenafil 50mg from prescription-only to Pharmacy, sold after a discussion with the pharmacist. It is the origin of the split we still show today: the same molecule priced one way over the counter and another through an online prescription service.
NHS sildenafil prescribing nearly tripled in a decade
Community prescribing of sildenafil in England rose from just over 1 million items to nearly 3 million across ten years, on NHS Digital figures. The rise followed cheap generics and the removal of restrictions that had limited NHS sildenafil to men whose ED stemmed from an underlying condition — the change that made an NHS prescription an option for most men.
Acne
NICE updates its acne guideline and withdraws the triamcinolone injection recommendation
NG198, the guideline covering acne management in primary and specialist care, was updated in August 2026. The recommendation on triamcinolone acetonide injections was withdrawn, and the guidance on considering oral isotretinoin was amended to take account of a person's psychological wellbeing, with referral to mental health services before starting where appropriate.
Dermatologists warn UK acne patients are over-exposed to oral antibiotics
The British Association of Dermatologists reports patients receiving oral antibiotics beyond recommended limits, alongside delays getting adequate treatment. Guidance is not to continue oral antibiotics past six months, and to pair them with a topical.
A clinical review of isotretinoin best practice
A practitioner-facing review covering how isotretinoin should be initiated, monitored and followed up under the current UK requirements. It also notes that acne prevalence in people aged 10 to 24 in the UK has risen over recent decades — a reminder that demand for treatment is growing while dermatology capacity is not.
Dermatologists publish updated guidance on the 2026 isotretinoin changes
The British Association of Dermatologists has published FAQs covering what the revised risk-minimisation measures mean in practice, including the new consent paperwork and the clinical audit starting this year.
Expert review of suspected psychiatric and sexual side effects of isotretinoin
The MHRA's published review of the evidence behind isotretinoin's psychiatric and sexual side-effect warnings, and the reasoning behind the current risk-minimisation measures.
What the isotretinoin prescribing changes mean for pharmacy teams
Community Pharmacy England's summary of the MHRA drug safety update, covering the revised risk-minimisation measures and the paperwork now required before treatment starts.
Isotretinoin prescribing rules eased — second prescriber no longer required for under-18s
Following a Commission on Human Medicines review, the requirement for a second approved clinician to agree isotretinoin treatment for under-18s was removed in January 2026, replaced by a new Acknowledgement of Risk form and a patient information video.
The review that produced the 2026 isotretinoin rule changes
The Commission on Human Medicines' review of how the 2023 isotretinoin recommendations were implemented — the underlying evidence document behind the January 2026 decision to drop the two-prescriber requirement for under-18s and replace it with an enhanced risk acknowledgement form, clinical audit and patient information resources. Worth reading if you want the reasoning rather than the headline.
Isotretinoin guidance clarified, and every prescribing service surveyed
An MHRA drug safety update clarified follow-up arrangements — the first appointment should be in person, later ones may be remote where appropriate, pregnancy testing may be medically supervised remotely, and patients should be asked about sexual function at follow-up. Both NHS and private isotretinoin services were required to complete a baseline survey, which is what produced the 2026 rule changes.
NICE cannot recommend clascoterone for acne after the company declined to submit evidence
NICE terminated its appraisal of clascoterone (Winlevi) for acne in people aged 12 and over because the company did not provide an evidence submission. No recommendation means no routine NHS funding route, which leaves the existing topical and oral options — and their private prices — as the practical choice.
The 2023 isotretinoin safety measures that started the current rules
The original package of measures following the Commission on Human Medicines review: additional oversight of treatment initiation for under-18s, strengthened counselling on psychiatric and sexual side effects, and the risk acknowledgement process. Everything the MHRA changed in 2025 and 2026 is an amendment to this.
Hay Fever
Tree pollen immunotherapy now recommended from age 5 upwards
The NICE appraisal of the 12 SQ-Bet sublingual immunotherapy tablet for moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen, updated to cover people aged 5 and over rather than adults alone. It treats the underlying allergy rather than suppressing symptoms, takes about three years, and is aimed at people not controlled by antihistamines and a steroid nasal spray used properly.
NICE extends allergy immunotherapy guidance to children
Updated final draft guidance recommended itulazax for children aged 5 to 17 with allergic rhinitis or conjunctivitis caused by birch pollen, extending a treatment previously recommended for adults. Relevant context for parents currently buying antihistamines season after season: for severe, poorly controlled allergy there is now an NHS route that is not symptom relief.
NHS antihistamine prescribing rose 18% in five years
NHS Business Services Authority analysis found 16,900,477 antihistamine items prescribed and dispensed in England in 2025/26, up 18.2% from 14,296,821 in 2021/22. Fexofenadine has been the most dispensed antihistamine since 2021/22. Demand is growing for medicines most people also buy over the counter — which makes the price you pay a choice rather than a given.
Met Office records high pollen levels across the UK
A forecast update during the peak of the season, covering which pollen types are driving symptoms and where levels are highest.
Met Office: no data supports the claim that pollen is worse this year
Warm spring weather brought symptoms on earlier in 2026, and the grass and weed seasons started sooner and stronger than usual — but the Met Office says there is no evidence the season is more severe overall, only that it shifted.
Met Office pollen forecast returns for the 2026 season
The daily five-day pollen forecast is live again. Antihistamines work best started before symptoms take hold, so the forecast is most useful in the days before a rise, not during one.
Royal Brompton researchers begin a hay fever study ahead of the season
A trial examining grass-pollen immunotherapy alongside dupilumab, aimed at the sizeable group whose symptoms are not controlled by standard antihistamines.
UKHSA guidance: hay fever affects around a quarter of UK adults and cases have trebled
Guidance from UKHSA and the Centre for Climate and Health Security states that hay fever affects 10 to 15% of children and 26% of adults in the UK, and that cases have trebled in the last 20 years. It also pushes back on hay fever being treated as trivial, citing disrupted sleep and missed work and school.
UKHSA guidance on outdoor airborne allergens
The official reference on pollen and other outdoor allergens in the UK — which plants matter, when their seasons run, and what the evidence says about exposure. Useful for working out which pollen actually affects you, which is the thing that turns a national pollen forecast into information about your own week.
NICE recommends the first immunotherapy for severe birch pollen allergy
A daily under-the-tongue immunotherapy tablet was recommended for adults with severe allergic rhinitis caused by birch pollen. Unlike antihistamines and nasal sprays, immunotherapy aims at the underlying allergy rather than the symptoms — a treatment course rather than a seasonal purchase, and an option for people whose symptoms are not controlled by standard treatment.
Boxed warnings added to montelukast over neuropsychiatric reactions
An MHRA review concluded the risk itself had not changed but was not well enough known, and added boxed warnings to every UK patient information leaflet. Reported reactions include sleep disorders, depression, anxiety and behaviour changes; hallucinations and suicidal thoughts are rare. Around 44 million prescriptions have been issued since 1998, with 1,223 suspected reports. Montelukast is prescribed for allergic rhinitis as well as asthma.
UKHSA on whether the hay fever season is starting earlier
A UKHSA explainer on what is and is not established about climate change and pollen: warmer temperatures can bring earlier and longer seasons, and the geographic spread of allergenic plants such as ragweed is on the watch list. It is the measured version of a claim that gets used to sell things every spring.
STI Testing
JCVI statement on meningococcal B vaccination in older children and young adults
The committee's advice on 4CMenB vaccination beyond infancy. It matters here because 4CMenB is the vaccine used in England's targeted gonorrhoea programme, and the evidence on how much protection it offers against gonorrhoea is still being gathered.
A&E opt-out blood testing has found around 2,000 undiagnosed HIV cases in four years
NHS England reported that routine opt-out testing in emergency departments across high-prevalence areas has identified about 1,900 people with HIV since April 2022. Strikingly, 93% of those diagnosed had no record of a previous HIV test — the programme reaches people who would not have tested through any other route. It now covers 88 areas of England.
STI diagnoses in England fell 8.3%, but syphilis rose among heterosexual women
UKHSA's latest annual figures show gonorrhoea down 10.9% and chlamydia down 10.3%, while syphilis in heterosexual women rose. Chlamydia remains 45% of all new diagnoses, and rates stay disproportionately high in under-25s.
STI diagnoses fell in England, with syphilis in gay and bisexual men lowest since 2016
UKHSA reported overall STI diagnoses in England down 8.3% between 2024 and 2025, gonorrhoea down 10.9% to 63,943 cases, and syphilis in gay and bisexual men down 18.7% to its lowest level since 2016. Read alongside the fall in testing volumes: fewer diagnoses and fewer tests produce the same graph for very different reasons.
UKHSA Health Protection Report carrying the 2025 STI figures for England
The surveillance bulletin covering the annual STI data release. Chlamydia was the most commonly diagnosed STI in 2025 at 151,163 diagnoses, followed by gonorrhoea at 63,943. Overall diagnoses fell 8.3% between 2024 and 2025. Read falling diagnoses alongside falling testing volumes rather than instead of them.
UKHSA sets out how doxyPEP will be monitored
A published monitoring and evaluation plan for doxycycline post-exposure prophylaxis, covering how provision is recorded by sexual health services and how the effect on antimicrobial resistance will be tracked. The resistance question is the main objection to doxyPEP, and this is the mechanism that will answer it rather than argue about it.
UK is first country to vaccinate against gonorrhoea — who is eligible
England began offering 4CMenB through specialist sexual health services in August 2025, primarily to gay and bisexual men at higher risk. Observational data suggests roughly 30–41% protection against gonorrhoea.
Quarterly surveillance: syphilis, gonorrhoea and ceftriaxone-resistant gonorrhoea
UKHSA's provisional quarterly figures for England, including cases of gonorrhoea resistant to ceftriaxone — the antibiotic of last resort for the infection.
UKHSA publishes a three-year response plan for syphilis
A plan setting out UKHSA activity from 2026 to 2029 to reduce syphilis incidence and the harms of untreated infection, and to address the inequalities in who gets it. Syphilis is the infection most often missing from cheaper home test panels, because it needs a blood sample rather than a swab or urine.
England's gonorrhoea vaccination programme, and the debate over its evidence
Coverage of the world-first programme and of the questions raised after the GoGoVax trial results were presented in February 2026. UKHSA is due to report effectiveness findings to the JCVI across 2026 to 2027.
HIV Action Plan sets a target of ending new HIV transmissions in England by 2030
The plan commits £108m from April 2026 to 2029 for emergency department opt-out HIV testing, £48m for hepatitis B and C testing in the same programme, and £5m to trial HIV home testing through the NHS App. For anyone weighing up paid home test kits, the free and expanding NHS routes are the comparison to make first.
How the gonorrhoea vaccination programme is being measured
UKHSA's surveillance plan for the targeted 4CMenB programme, covering uptake, effectiveness against symptomatic disease and asymptomatic infection, recurrent infection, co-infection and duration of protection. The programme was launched on partial and contested evidence, so what this surveillance reports will matter more than the launch announcements did.
UK publishes its first national guideline on doxycycline post-exposure prophylaxis
BASHH issued the UK's first clinical guideline on doxyPEP for preventing syphilis — a single 200mg dose of doxycycline within 24 hours and no later than 72 hours after sex — making the UK one of the first countries to give formal direction on the strategy. It is prevention, not treatment, and sits alongside testing rather than replacing it.
Ceftriaxone-resistant and extensively drug-resistant gonorrhoea both rising
UKHSA reported 17 ceftriaxone-resistant gonorrhoea cases between January 2024 and March 2025, against 16 across the preceding two years, and 9 extensively drug-resistant cases against 5. Small numbers, clear direction. The advice is unchanged and unglamorous: condoms, and testing after condomless sex with new or casual partners.
JCVI advice that led to the gonorrhoea vaccination programme
The Joint Committee on Vaccination and Immunisation advised a targeted gonorrhoea vaccination programme using the 4CMenB vaccine, alongside routine mpox vaccination for those at highest risk, both offered opportunistically through specialist sexual health services. This is the advice the 2025 rollout implemented.
Why men are no longer proactively offered chlamydia screening
The National Chlamydia Screening Programme was refocused on reducing the reproductive harm of untreated infection in young women. In community settings such as GPs and pharmacies, screening is now proactively offered to young women only. Anyone can still be tested on request, and men are tested where there is an indication — a partner with chlamydia, or symptoms.
More
Pharmacy First consultations to be clinically audited under the 2026/27 quality scheme
NHS England said the Pharmacy Quality Scheme for 2026/27 will include a clinical audit of Pharmacy First consultations, assessing the quality and completeness of the clinical records made. Record quality is the part of a pharmacy consultation a patient never sees and cannot compare on.
MHRA safety roundup, August 2026
The monthly consolidation of MHRA safety communications — drug safety updates, recalls and defect notifications issued during the month. The single most reliable place to check whether anything has been said about a medicine you take, rather than waiting for it to reach the news.
Official statistics on how often UK medicine supply is disrupted
The Department of Health and Social Care publishes data on medicine supply disruption across the UK. It is the honest backdrop to any price comparison: a listed price is only useful if the pharmacy can actually supply the strength you need, and supply notifications are why a cheap option sometimes cannot be filled.
MHRA safety roundup, July 2026
The regulator's monthly consolidation of drug and device alerts, recalls and supply mitigations affecting UK pharmacies.
Each integrated care board gets £51,000 to implement pharmacy independent prescribing
NHS England wrote to integrated care boards in England confirming £51,000 each, for 2026/27 only, to support implementing independent prescribing from autumn 2026. The size of the figure is the story: a one-year sum per ICB to stand up a service that changes where a lot of routine prescribing happens.
The 2026/27 community pharmacy contract in full
The contractual framework behind the announcement, setting out what community pharmacy is funded to do this year. It is the document that determines which services you can get at a pharmacy counter without a prescription — the practical boundary between a free NHS route and a paid private one.
MHRA safety roundup, May 2026
May's consolidated alerts, including interim foreign-stock supply arrangements used to bridge UK shortages.
Community pharmacists to start prescribing under an expanded Pharmacy First
A £340m increase takes community pharmacy funding to £3.636bn for 2026/27, introducing NHS-funded independent prescribing as an extension of Pharmacy First from autumn 2026. Candidate new pathways under consideration include allergic conjunctivitis — which would put a hay fever consultation on the high street rather than behind a GP appointment.
NHS-funded independent prescribing arrives in community pharmacies this autumn
The Department of Health and Social Care confirmed NHS-funded independent prescribing will roll out in community pharmacies in England from autumn 2026, letting pharmacists with the qualification assess patients and prescribe directly. A structural change to who can prescribe on the high street, and in time to what has to be bought privately at all.
Market items link to the publication that reported them. MedsLens is not affiliated with any manufacturer or pharmacy named here, and nothing on this page is medical advice — talk to a prescriber about whether a treatment is right for you.